Association with UBE2T expression and clinicopathologic factors
The scatter plot showed the difference of UBE2T expression between normal and tumor samples (P < 0.01), Fig. 1A. We next used UALCAN to explore the relationship of expression of UBE2T and clinical factors. In age subgroup (normal-vs-age (21-40yrs), normal-vs-age (41-60yrs), normal-vs-age (61-80yrs) and normal-vs-age (81-100yrs)) analysis the transcription level of UBE2T was essentially higher in OC patients than healthy individuals; race subgroup (normal-vs-Caucasian, normal-vs-AfricanAmerican and normal-vs-Asian); tumor grade subgroup (normal-vs-Grade 1, normal-vs-Grade 2, normal-vs-Grade 3 and normal-vs-Grade 4) analysis the UBE2T was also significantly higher in OC patients Fig. 1B-1E.
GSEA recognizes UBE2T related signaling pathway
In order to recognize signaling pathways which might be differentially initiated in OC, we led GSEA analysis among low and high UBE2T expression data sets (FDR P < 0.05, NOM P < 0.05). We chose the most significantly enriched signaling pathways dependent on normalized enrichment score (NES) Table 1. The results show that cell cycle, DNA replication, RNA degradation, some cancers, spliceosome, Huntington’s disease, oxidative phosphorylation are differentially enriched in UBE2T high expression phenotype Fig. 2.
Table 1
Gene sets enriched in phenotype high
Gene Symbol | Amplification | Homozygous Deletion | Mutation | Total Alteration |
HES1 | 13.6 | 0.3 | 0.3 | 14.2 |
RFC4 | 13.3 | 0 | 0 | 13.3 |
FAAP24 | 7.9 | 0 | 0 | 7.9 |
UBE3C | 6.3 | 0.3 | 0 | 6.6 |
UBE2Q1 | 4.7 | 0 | 0 | 4.7 |
Survival and cBioPortal results
Overall survival (OS), progression-free survival (PFS) and post-progression survival (PPS) analysis demonstrated that OC with UBE2T -high had a more terrible prognosis than that with UBE2T -low (P < 0.05) Fig. 3. In order to decide the biological interaction network of UBE2T in OC, we applied to tab Network in cBioPortal and the 50 most as often altered neighbor genes of UBE2T were showed utilizing Network and the most frequent alterations were HES1 (14.2%) (Fig. 4 and Table 2).
Gene Symbol
|
Amplification
|
Homozygous
Deletion
|
Mutation
|
Total
Alteration
|
HES1
|
13.6
|
0.3
|
0.3
|
14.2
|
RFC4
|
13.3
|
0
|
0
|
13.3
|
FAAP24
|
7.9
|
0
|
0
|
7.9
|
UBE3C
|
6.3
|
0.3
|
0
|
6.6
|
UBE2Q1
|
4.7
|
0
|
0
|
4.7
|
Table 2. The type and frequency of UBE2T neighbor gene alterations in OC (cBioPortal).
Immune infiltrates and miRNAs in correlation with UBE2T in OC
OC expression of UBE2T immune infiltrates (B cells, CD4 + T cells, CD8 + T cells, neutrophils, macrophages, and dendritic cells) correlation between the abundance of statistical significance (P < 0.05, Fig. 5A). Cumulative survival showed that UBC2T immunosuppressive dendritic cells in OC were statistically significant (P < 0.05), indicating that dendritic cells significantly affected prognosis and warrant further study and exploration (Fig. 5B). A box plot was introduced to demonstrate the distribution of each immunization subgroup in each copy number state with UBE2T in OC. According to the cumulative weighted context + + score, the top three of the 1169 miRNA families associated with the gene UBE2T in OC are hsa-miR-5580-3p, hsa-miR-3652 and hsa-miR-4430. Figure 6A shows conserved sites of the widely conserved miRNA family in vertebrates. To examine the function of the identified 1169 miRNAs, bioconcentration was performed by the Funrich database. Biological processes are significantly rich in nucleobase regulation, signal transduction, cellular communication, transport, cell growth, and regulation of cellular tissue and biogenesis. Cellular components are mainly enriched in the nucleus, cytoplasm, Golgi apparatus, endosomes, lysosomes and early endosomes. Molecular functions are mainly enhanced by transcription factor activity, transcriptional regulatory activity, protein serine, GTPase activity and ubiquitin-specific protease activity; biological pathways are abundant, including Glypican pathway, proteoglycan syndecan-mediated signaling events, VEGF and VEGFR signals Network, TRAIL signaling pathway, sphingosine 1-phosphate (S1P) pathway and ErbB signaling pathway Fig. 6B-6E.